Navigation Links
Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer

AMSTERDAM, September 3, 2014 /PRNewswire/ --


~ Clinical and Business Development expert re-joins the Company ~ 

Kiadis Pharma B.V. ("Kiadis Pharma", "Kiadis" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces the appointment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer.

Jeroen Rovers was most recently Chief Medical Officer at Ceronco Biosciences. Prior to that he was VP Medical Affairs at Kiadis Pharma and has remained a consultant to the Company until his re-appointment on September 1, 2014. Jeroen worked at Organon (acquired by Schering - Plough in 2007) between 2005-2008, latterly as Director of Clinical Development and Business Development. Jeroen has more than 15 years of professional experience in clinical development within academia and the pharmaceutical industry. He has a strong background in cell based therapeutics/advanced-therapy medicinal products (ATMPs) and has a wealth of experience in oncology, hematology and other immunology-related fields such as organ transplantation. Jeroen has significant experience in conducting clinical trials in various oncology indications covering all phases of the clinical development pathway (Phase I to III), having coordinated clinical trials in the EU for various pharmaceutical companies. He has also been involved in early and later stage development of cancer immune therapies and conducted his doctoral thesis on the use of light-activated drugs in the treatment of tumors.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: "Jeroen joins Kiadis with a deep knowledge and clear understanding of ATIR and of the potential of its underlying technology platform. I am delighted to welcome him as a key member of our Executive Management Team at Kiadis at this important time for the Company. His medical and clinical expertise, coupled with business development connections, will be extremely useful given the stage of our Phase II program and the interest we have been seeing in our field.  We feel he will continue to make a valuable addition to our team and help us to make ATIR a reality for patients and to develop it to its full potential. On behalf of the team and our Board of Directors we wish to thank Edwin Wagena, Chief Development Officer, for his contribution to Kiadis in the earlier stages since 2008 and wish him all success in his future career."

Jeroen Rovers, Chief Medical Officer, added: "I am extremely excited to have the opportunity to rejoin Kiadis Pharma and be able to focus on its T-cell based immunotherapy product ATIR™, which has the potential to enable safe and efficacious use of partially mismatched (haploidentical) family members as donors for patients suffering from hematologic malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). All patients in need of a stem cell donor, whether after conventional treatments or innovative approaches like Chimeric Antigen Receptor (CAR) T-cell therapies, will potentially benefit from ATIR.  I believe ATIR is a truly innovative product and has the potential to become a key part of the next generation treatments of blood cancers."

About ATIR™ 

ATIR™ is a T-cell immunotherapy based medicinal product enabling stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who do not have a standard of care stem cell donor available. A hematopoietic stem cell transplantation (HSCT) is the only potentially curative option for many patients but a matching donor is available for only half of the patients in need. ATIR™ thus has the potential to address this unmet need and to make a HSCT available for all patients worldwide.

Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease (GvHD) are selectively eliminated using proprietary technology to produce ATIR™. ATIR™ is administered as an adjunctive treatment after a T-cell depleted haploidentical HSCT facilitating early immune reconstitution without causing life-threatening (acute) GvHD.

ATIR™ dovetails current approaches that render a patient eligible for a stem cell transplantation. Usually, only patients in remission are considered eligible for such a transplantation and so approaches that put refractory patients into remission, such as Chimeric Antigen Receptor (CAR) T-cell therapies, will increase the need for donors and potentially, therefore, the need for ATIR™.

In a Phase I/II study in which high-risk leukemia patients with very poor prognosis were treated with escalating doses of ATIR™ after a haploidentical HSCT, long-term safety, efficacy and proof of concept were confirmed in terms of absence of Grade III/IV (life-threatening) acute GvHD, reduced rates of infection, reduced Transplant Related Mortality and high Overall Survival. Positive follow-up results from this study demonstrating 67% survival after five years and no Transplant Related Mortality in the nine patients who received an efficacious dose of ATIR™ were recently reported.

An international multi-center Phase II study including patients with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome, to corroborate and extend the safety and efficacy results from the Phase I/II study, is now ongoing with topline data expected in the second half of 2014.  

ATIR™ has been granted Orphan Drug Designation both in the EU and the USA. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.

About Kiadis Pharma 

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on the development of innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders, an area of significant unmet medical need.

Kiadis Pharma's lead product is ATIR™, a T-cell immunotherapy based medicinal product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™. Kiadis Pharma is working under a GMP manufacturing license and GMP certificate for its Quality Control laboratory.

Kiadis Pharma is supported by a strong group of leading international investors including LSP, DFJ Esprit, Alta Partners, Quest for Growth, NOM and MedSciences Capital. Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at:  

Company Contact:
Manfred Ruediger, CEO
Kiadis Pharma
Entrada 231-234
1114 AA Amsterdam-Duivendrecht
The Netherlands
Tel. +31-20-314-02-50

Media and Investor Contact:
Mary-Jane Elliott, Amber Bielecka, Jessica Hodgson, Lindsey Neville
Consilium Strategic Communications
Tel: +44-(0)-203-709-5708    

SOURCE Kiadis Pharma
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate
2. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
8. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
11. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
Breaking Medicine News(10 mins):